Literature DB >> 12649354

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.

Masayuki Fujino1, Naoko Funeshima, Yusuke Kitazawa, Hiromitsu Kimura, Hiroshi Amemiya, Seiichi Suzuki, Xiao-Kang Li.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a T-cell-dependent autoimmune disease that reproduces the inflammatory demyelinating pathology of multiple sclerosis (MS). We investigated the efficacy and mechanism of immunosuppression against EAE by administering 2-amino-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride (FTY720) in Lewis rats immunized with myelin basic protein together with complete Freund's adjuvant. FTY720 treatment almost completely protected the rats against disease. The protection by FTY720 was associated with a dramatic reduction in the number of lymphocytes staining for T-cell receptors in the spinal cord as examined by immunohistochemistry. The mRNA expression of Th1 cytokines interleukin (IL)-2, IL-6, and interferon-gamma in the spinal cord was also reduced dramatically as assessed by reverse-transcription polymerase chain reaction. Furthermore, lymphocytes isolated from the spleen of FTY720-treated rats were transferred into naive recipient rats against EAE manifestation by reducing both disease incidence and clinical score. These results suggested that the protective anti-inflammatory effect of treatment with FTY720 was, to a large extent, due to the inhibition of encephalitogenic T-cell responses and/or their migration into the central nervous system and may be a potential candidate for use in treating patients with MS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649354     DOI: 10.1124/jpet.102.045658

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  98 in total

Review 1.  Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Authors:  Ludwig Kappos; Jens Kuhle; Achim Gass; Lutz Achtnichts; Ernst-Wilhelm Radue
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].

Authors:  O Aktas; J Ingwersen; B Kieseier; P Küry; R Hohlfeld; H-P Hartung
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

Review 3.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 4.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 5.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 6.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

Review 7.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

Review 8.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 9.  Sphingolipids in spinal cord injury.

Authors:  Zachary B Jones; Yi Ren
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-08-05

Review 10.  Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system.

Authors:  Edward J Goetzl; Wengang Wang; Christine McGiffert; Mei-Chuan Huang; Markus H Gräler
Journal:  J Cell Biochem       Date:  2004-08-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.